Latest news

For Australians living with MS, REBIF will no longer be available on the Pharmaceutical Benefits Scheme (PBS) from 1 December 2022.

Who might be these invisible heroes? These people are commonly known as ‘carers’, but ‘common’ and ‘ordinary’ they are not.

On 14 October 2022, the Pharmaceutical Benefits Advisory Committee (PBAC) recommended that Evusheld not be listed on the Pharmaceutical Benefits Scheme (PBS). However, this may be revised in the future and access will remain through current schemes.

"We are so grateful that MSWA looks after us"
44-year-old Jasmin Franklin was born with a rare condition called Klippel-Feil Syndrome. Remarkably, the diagnosis took 40 years to be found.

Watch Jasmin's incredible story…

Vumerity® (diroximel fumarate) will be listed under the Pharmaceutical Benefit Scheme (PBS).

Ros Harman has announced her resignation from the MSWA Board after 18 years of service and valued contribution.

MSWA is proud to be funding this important West Australian research, led by Professor Bruni Meloni, that will potentially provide the first effective treatment to minimise the damage that occurs in the early phases of stroke.

The survey, where 1,748 Australians (of which 525 are living with MS) participated, revealed there is a disconnect between expectations and workplace realities for those with a health condition.

Margaret Cable, from Toodyay, was diagnosed with MS in the early days of COVID-19. Her story is a heartening example of “I connect, we connect” – the official tagline of World MS Day 2022.

International Nurses Day is our chance to say thank you and show our appreciation to those who go above and beyond each and every day, our nurses.